Who / What
Zanzalintinib is an investigational drug currently undergoing clinical studies that inhibits several receptor tyrosine kinases, including VEGFR2, MET, AXL, and MERTK. It is also known as XL092. The compound is being developed by Exelixis.
Background & History
The compound was first identified as XL092 and designed to target key tyrosine kinases in cancer therapy. Exelixis developed it with the goal of treating colorectal cancer and renal cell carcinoma. Pre‑clinical studies demonstrated its activity against tumors driven by VEGFR2, MET, AXL, and MERTK. The drug has progressed to a phase 3 trial (STELLAR‑303).
Why Notable
Zanzalintinib’s broad kinase inhibition makes it a promising multi‑targeted therapy in oncology. It is the focus of a phase 3 study in metastatic colorectal cancer when combined with atezolizumab. Successful results could provide a new treatment option for patients who have progressed on standard therapy.
In the News
The STELLAR‑303 study is currently enrolling patients in the United States. Results are expected to clarify the benefit of combining zanzalintinib with atezolizumab over regorafenib. The trial highlights the growing interest in pairing kinase inhibitors with immunotherapy.
